Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30⁺ lymphoma patients.

ABSTRACT:

SUBMITTER: Wang D 

PROVIDER: S-EPMC6978321 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature